$7.02
0.00%
Nasdaq, Thu, Apr 17 2025
ISIN
US00437E1029
Symbol
ACCD
Sector
Industry

Accolade Stock price

$7.02
+0.02 0.29% 1M
+3.44 96.09% 6M
+3.60 105.26% YTD
-1.68 19.31% 1Y
-6.00 46.08% 3Y
-22.68 76.36% 5Y
-22.68 76.36% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.00 0.00%
ISIN
US00437E1029
Symbol
ACCD
Sector
Industry

Key metrics

Market capitalization $575.59m
Enterprise Value $588.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.32
P/S ratio (TTM) P/S ratio 1.29
P/B ratio (TTM) P/B ratio 1.82
Revenue growth (TTM) Revenue growth 14.99%
Revenue (TTM) Revenue $446.72m
EBIT (operating result TTM) EBIT $-85.98m
Free Cash Flow (TTM) Free Cash Flow $-12.74m
Cash position $225.48m
EPS (TTM) EPS $-2.25
P/E forward negative
P/S forward 1.23
EV/Sales forward 1.26
Short interest 2.55%
Show more

Is Accolade a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Accolade Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Accolade forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Accolade forecast:

Hold
100%

Financial data from Accolade

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Nov '24
+/-
%
447 447
15% 15%
100%
- Direct Costs 275 275
6% 6%
62%
172 172
33% 33%
38%
- Selling and Administrative Expenses 122 122
3% 3%
27%
- Research and Development Expense 92 92
6% 6%
21%
-42 -42
51% 51%
-9%
- Depreciation and Amortization 44 44
4% 4%
10%
EBIT (Operating Income) EBIT -86 -86
35% 35%
-19%
Net Profit -180 -180
47% 47%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Accolade directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Accolade Stock News

Neutral
CNBC
13 days ago
Transcarent on Tuesday announced it has completed its $621 million acquisition of Accolade. Accolade shareholders received $7.03 per share in cash, and the company will no longer be listed on the Nasdaq.
Neutral
Business Wire
13 days ago
SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)-- #HealthWayFinding--Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care....
Neutral
GlobeNewsWire
25 days ago
SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting”) held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission.
More Accolade News

Company Profile

Accolade, Inc. is an emerging growth company, which engages in the provision of personalized, technology-enabled solutions through a technology platform. It offers Accolade Total Benefits and Accolade Total Care. Accolade Total Benefits focuses on member benefits engagement and Accolade Total Care help guides members to healthcare providers. The company was founded by Thomas K. Spann and J. Michael Cline in 2007 and is headquartered in Seattle, WA.

Head office United States
CEO Rajeev Singh
Employees 2,400
Founded 2007
Website www.accolade.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today